Caris Life Sciences secures $830m funding to expand cancer care platform
The new funding gives Caris Life Sciences a post-money valuation of $7.83bn
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 May 21
The new funding gives Caris Life Sciences a post-money valuation of $7.83bn
30 Apr 21
OptiLight is an IPL device indicated for patients aged 22 years and above with symptoms of DED due…
29 Apr 21
The two biomarkers include high-sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP)
27 Apr 21
Lucira CHECK IT Covid-19 self-test is said to be the first self-test authorised by Health Canada for individuals…
22 Apr 21
VERITAS Vision System provide surgeons with enhanced stability and control throughout the phacoemulsification process
12 Apr 21
The LUCIRA Covid-19 All-In-One Test Kit is an FDA-authorised, prescription, molecular diagnostic test that delivers results within 30…
09 Apr 21
The acquisition of Mobidiag will strengthen Hologic’s international and diagnostics businesses
08 Apr 21
Elecsys Anti-p53 is a high precision immunoassay that leverages well-established electrochemiluminescence immunoassay (ECLIA) technology
07 Apr 21
EC approval is supported by the results from XIENCE 28 and XIENCE 90 clinical trials
06 Apr 21
The CONSTRUX Mini Ti System is designed with nanoscale surface features and is said to be the first…